

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

BD Biosciences: Canto II Flow Cytometer

RRID:SCR_018056

Type: Tool

Proper Citation

BD Biosciences: Canto II Flow Cytometer (RRID:SCR_018056)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/facscanto-ii>

Proper Citation: BD Biosciences: Canto II Flow Cytometer (RRID:SCR_018056)

Description: Benchtop flow cytometer features reliable performance and accurate results for experiments requiring up to 10 parameters. Fixed alignment flow cell minimizes startup time and improves reproducibility. Patented optical design maximizes signal detection and increases sensitivity and resolution for each color in multicolor assay.

Synonyms: Canto II

Resource Type: instrument resource

Keywords: ABRF, Flow Cytometer, benchtop analyzer, cell analyzer, flow cytometry, multicolor analysis, BD FACSCanto II, instrument, equipment

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018056.pdf

Resource Name: BD Biosciences: Canto II Flow Cytometer

Resource ID: SCR_018056

Alternate IDs: Model_Number_Canto II

Alternate URLs: https://www.bdbiosciences.com/content/dam/bdb/marketing-documents/BD_FACSCanto_II_brochure.pdf

Record Creation Time: 20220129T080338+0000

Record Last Update: 20260815T182548+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: Canto II Flow Cytometer.

No alerts have been found for BD Biosciences: Canto II Flow Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Grauers Wiktorin H, et al. (2026) Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients. Biomarker research, 14(1).

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

García-Vicente R, et al. (2026) The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(2), 375.

Corona M, et al. (2026) Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. Journal for immunotherapy of cancer, 14(3).

Chatterjee E, et al. (2026) The HDAC Inhibitor RM-3-22 Suppresses Triple-Negative Breast Cancer by Uncoupling Autophagy to Drive FSP1-Dependent Ferroptosis. Translational research : the journal of laboratory and clinical medicine, 295, 95.

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. Cancer research, 86(2), 485.

Hunt KS, et al. (2026) Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway. Cancer immunology research, 14(7), 1068.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. Apoptosis : an international journal on programmed cell death, 31(5).

Braams M, et al. (2026) ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development. Cell reports. Medicine, 7(7), 102879.

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. Angiogenesis, 29(2), 18.

Marchetti S, et al. (2026) Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 197, 119183.

Wang Q, et al. (2026) Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer. *Cancer research*, 86(10), 2395.

Kasahara S, et al. (2026) Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial. *iScience*, 29(8), 116817.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. *Experimental dermatology*, 34(5), e70123.

Bleve A, et al. (2025) ROR γ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. *Cancer discovery*, 15(7), 1505.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.

Verdegaal EME, et al. (2025) Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFN γ . *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(13), 2628.

Shia CS, et al. (2025) Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. *Molecular cancer therapeutics*, 24(12), 1938.

Choe M, et al. (2025) Preclinical Evaluation of Folate Receptor- γ Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma. *Cancer research communications*, 5(9), 1701.

Eguchi S, et al. (2025) CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma. *Molecular therapy. Oncology*, 33(4), 201051.